BioNTech and Pfizer announce the latest status of the vaccine they have developed
In the race to develop vaccine against Kovid-19, BioNTech-Pfizer was the first to take the lead in the Western world. 95 percent efficiency was achieved in the final analysis. Pfizer announced that they would apply for emergency use authorization in the US within a few days.
German scientists established by the Turkey-based biotechnology company’s production and distribution of the vaccine developed by biontech yapılabilecekcak soon.
Pfizer said they have two months of data on the vaccine’s safety.
It is pointed out that the effectiveness of the vaccine is consistent throughout the age and ethnicity demography, it does not have significant side effects, and that vaccination can be applied worldwide. In the statement, it was emphasized that the effectiveness rate of the vaccine in adults over 65, one of the most risky groups, exceeded 94 percent.